Citizens Financial Group Inc. RI Increases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Citizens Financial Group Inc. RI boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.6% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 6,321 shares of the biopharmaceutical company’s stock after buying an additional 337 shares during the period. Citizens Financial Group Inc. RI’s holdings in Gilead Sciences were worth $530,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Manning & Napier Advisors LLC bought a new position in shares of Gilead Sciences in the second quarter worth about $25,328,000. Legal & General Group Plc increased its position in shares of Gilead Sciences by 0.8% during the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock worth $851,743,000 after acquiring an additional 93,068 shares during the period. IRON Financial LLC bought a new stake in shares of Gilead Sciences during the third quarter valued at approximately $830,000. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Gilead Sciences by 13.1% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company’s stock valued at $19,630,000 after purchasing an additional 33,162 shares during the period. Finally, Cetera Investment Advisers grew its stake in Gilead Sciences by 127.6% in the first quarter. Cetera Investment Advisers now owns 213,901 shares of the biopharmaceutical company’s stock worth $15,668,000 after purchasing an additional 119,909 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have weighed in on GILD. Cantor Fitzgerald upped their target price on Gilead Sciences from $70.00 to $80.00 and gave the stock a “neutral” rating in a report on Thursday, November 7th. UBS Group lifted their price objective on Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a report on Thursday. BMO Capital Markets increased their target price on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Citigroup began coverage on shares of Gilead Sciences in a research report on Thursday, November 14th. They issued a “buy” rating and a $125.00 price target for the company. Finally, Oppenheimer lifted their price objective on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Twelve research analysts have rated the stock with a hold rating, eleven have issued a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $95.41.

Gilead Sciences Stock Up 0.5 %

Shares of GILD stock opened at $90.19 on Friday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90. The firm has a market capitalization of $112.40 billion, a PE ratio of 1,002.11, a P/E/G ratio of 2.78 and a beta of 0.17. The stock’s 50-day simple moving average is $87.43 and its 200-day simple moving average is $76.86.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same period in the previous year, the business posted $2.29 EPS. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. Equities analysts expect that Gilead Sciences, Inc. will post 4.38 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be issued a $0.77 dividend. The ex-dividend date of this dividend is Friday, December 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.42%. Gilead Sciences’s dividend payout ratio (DPR) is presently 3,422.22%.

Insider Buying and Selling

In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the transaction, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The trade was a 27.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Merdad Parsey sold 25,590 shares of the stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the sale, the insider now directly owns 99,599 shares in the company, valued at approximately $9,113,308.50. The trade was a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 56,947 shares of company stock valued at $4,968,674 over the last ninety days. Company insiders own 0.16% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.